- More Files
The standard curve is for the purpose of illustration only and should not be used to calculate unknowns. A standard curve should be generated each time the assay is performed.
- Specification
Product Description
COVID-19 Neutralizing Antibody ELISA Kit is an indirect enzyme-linked immunoassay (ELISA) for semi-quantitative determination of COVID-19 neutralizing antibody.
Supplied Product
Kit content:
1. Capture Plate
2. Spike RBD Tag Fusion Protein
3. SARS-CoV-2 Neutralizing Antibody Calibrator
4. Positive Control
5. Negative Control
6. HRP Anti-Tag Antibody
7. Blocking Buffer Concentrate (10X)
8. Assay Diluent Concentrate (10X)
9. Wash Buffer Concentrate (10X)
10. TMB Solution
11. Stop Solution
12. Plate SealerSuitable Sample
Human Serum
Sample Volume
30 uL
Detection Method
Colorimetric
Assay Type
Semi-quantitative
Regulatory Status
For research use only (RUO)
Quality Control Testing
Standard curve calibration
The standard curve is for the purpose of illustration only and should not be used to calculate unknowns. A standard curve should be generated each time the assay is performed.
Storage Instruction
Store at -20°C:
SARS-CoV-2 Neutralizing Antibody Calibrator
Positive Control
Negative Control
HRP Anti-Tag Antibody
Blocking Buffer Concentrate (10X)
Assay Diluent Concentrate (10X)
Store at room temperature:
Wash Buffer Concentrate (10X)
Stop Solution
Plate Sealer
Store at 2-8°C:
Capture Plate
Spike RBD Tag Fusion Protein
TMB Solution - Applications
Semi-Quantification
- Publication Reference
- Safety and Immunogenicity of a Recombinant Receptor Binding Domain-Based Protein Subunit Vaccine (Noora Vaccine™) Against COVID-19 in Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial.
Jafar Salimian, Ali Ahmadi, Jafar Amani, Gholamreza Olad, Raheleh Halabian, Ali Saffaei, Masoud Arabfard, Mojtaba Nasiri, Shahram Nazarian, Hassan Abolghasemi, Gholam Hossein Alishiri.
Journal of Medical Virology 2023 Feb; 95(2):10.1002/jm.
Application：Neutralization, Human, Human serum.
- Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models.
Shahram Nazarian, Gholamreza Olad, Raziyeh Abdolhamidi, Mohammad Javad Motamedi, Rouhollah Kazemi, Emad Kordbacheh, Alireza Felagari, Hanieh Olad, Ali Ahmadi, Alireza Bahiraee, Parisa Farahani, Leila Haghighi, Faezeh Hassani, Vahideh Hajhassan, Mona Nadi, Abdolkarim Sheikhi, Jafar Salimian, Jafar Amani.
Molecular Immunology 2022 Sep; 149:107.
Application：ELISA, Human, Vero cells.
- Safety and Immunogenicity of a Recombinant Receptor Binding Domain-Based Protein Subunit Vaccine (Noora Vaccine™) Against COVID-19 in Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial.